212 related articles for article (PubMed ID: 8063403)
1. Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan.
Casadevall A; DeShaw M; Fan M; Dromer F; Kozel TR; Pirofski LA
Infect Immun; 1994 Sep; 62(9):3864-72. PubMed ID: 8063403
[TBL] [Abstract][Full Text] [Related]
2. Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune mice.
Nussbaum G; Anandasabapathy S; Mukherjee J; Fan M; Casadevall A; Scharff MD
Infect Immun; 1999 Sep; 67(9):4469-76. PubMed ID: 10456888
[TBL] [Abstract][Full Text] [Related]
3. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.
Pirofski L; Lui R; DeShaw M; Kressel AB; Zhong Z
Infect Immun; 1995 Aug; 63(8):3005-14. PubMed ID: 7622223
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies.
Mukherjee J; Kozel TR; Casadevall A
J Immunol; 1998 Oct; 161(7):3557-68. PubMed ID: 9759877
[TBL] [Abstract][Full Text] [Related]
5. The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies.
Casadevall A; Scharff MD
J Exp Med; 1991 Jul; 174(1):151-60. PubMed ID: 1676047
[TBL] [Abstract][Full Text] [Related]
6. Aspects of antigen mimicry revealed by immunization with a peptide mimetic of Cryptococcus neoformans polysaccharide.
Valadon P; Nussbaum G; Oh J; Scharff MD
J Immunol; 1998 Aug; 161(4):1829-36. PubMed ID: 9712050
[TBL] [Abstract][Full Text] [Related]
7. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.
Casadevall A; Mukherjee J; Devi SJ; Schneerson R; Robbins JB; Scharff MD
J Infect Dis; 1992 Jun; 165(6):1086-93. PubMed ID: 1583327
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis for immunoglobulin M specificity to epitopes in Cryptococcus neoformans polysaccharide that elicit protective and nonprotective antibodies.
Nakouzi A; Valadon P; Nosanchuk J; Green N; Casadevall A
Infect Immun; 2001 May; 69(5):3398-409. PubMed ID: 11292763
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization.
Mukherjee J; Casadevall A; Scharff MD
J Exp Med; 1993 Apr; 177(4):1105-16. PubMed ID: 8459205
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Cryptococcus neoformans capsular glucuronoxylomannan polysaccharide with monoclonal antibodies.
Todaro-Luck F; Reiss E; Cherniak R; Kaufman L
Infect Immun; 1989 Dec; 57(12):3882-7. PubMed ID: 2680986
[TBL] [Abstract][Full Text] [Related]
11. Variable region gene utilization and mutation in a group of neutralizing murine anti-human immunodeficiency virus type 1 principal neutralizing determinant antibodies.
Pirofski LA; Thomas EK; Scharff MD
AIDS Res Hum Retroviruses; 1993 Jan; 9(1):41-9. PubMed ID: 7678971
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of murine monoclonal anti-CD4. Epitope recognition, idiotype expression, and variable region gene sequence.
Lohman KL; Attanasio R; Buck D; Carrillo MA; Allan JS; Kennedy RC
J Immunol; 1992 Nov; 149(10):3247-53. PubMed ID: 1385519
[TBL] [Abstract][Full Text] [Related]
13. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library.
Beenhouwer DO; May RJ; Valadon P; Scharff MD
J Immunol; 2002 Dec; 169(12):6992-9. PubMed ID: 12471134
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies.
Cleare W; Cherniak R; Casadevall A
Infect Immun; 1999 Jun; 67(6):3096-107. PubMed ID: 10338526
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice.
Mukherjee S; Lee S; Mukherjee J; Scharff MD; Casadevall A
Infect Immun; 1994 Mar; 62(3):1079-88. PubMed ID: 8112842
[TBL] [Abstract][Full Text] [Related]
16. Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.
Mukherjee J; Scharff MD; Casadevall A
Infect Immun; 1995 Sep; 63(9):3353-9. PubMed ID: 7642262
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy.
Mukherjee J; Feldmesser M; Scharff MD; Casadevall A
Antimicrob Agents Chemother; 1995 Jul; 39(7):1398-405. PubMed ID: 7492075
[TBL] [Abstract][Full Text] [Related]
18. Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans.
Valadon P; Nussbaum G; Boyd LF; Margulies DH; Scharff MD
J Mol Biol; 1996 Aug; 261(1):11-22. PubMed ID: 8760499
[TBL] [Abstract][Full Text] [Related]
19. Immunoelectronmicroscopic characterization of monoclonal antibodies (MAbs) against Cryptococcus neoformans.
Todaro-Luck F; White EH; Reiss E; Cherniak R
Mol Cell Probes; 1989 Dec; 3(4):345-61. PubMed ID: 2482437
[TBL] [Abstract][Full Text] [Related]
20. Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.
Duro RM; Netski D; Thorkildson P; Kozel TR
Clin Diagn Lab Immunol; 2003 Mar; 10(2):252-8. PubMed ID: 12626451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
